Navigation Links
Immtech to Present at The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Date:11/5/2007

NEW YORK, Nov. 5 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) announced today that it will present at the Acumen BioFin(TM) Rodman & Renshaw 9th Annual Healthcare Conference.

On Tuesday, November 6 at 2:40 p.m. Eastern Time, Immtech is scheduled to present in the Hubbard Room, 5th floor, at the New York Palace Hotel in New York City.

Immtech will hold a conference call on Friday, November 9, at 3.00 p.m. (ET) to present an update on the Company's progress. The User Access Code is # 23641366. Investors and interested parties in the U.S. are invited to join the call by dialing (888) 338-8374 and callers outside the U.S. should call (706) 902-3163. To register, please call no later than 10 minutes prior to the scheduled start of the call. Information to access a recording of the conference call will be available starting on November 12 from the Immtech Pharmaceuticals website (http://www.immtechpharma.com).

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious diseases, and the company is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African sleeping sickness), and a well-defined, expanding library of compounds targeting drug-resistant Gram-positive bacteria, fungal infections, Hepatitis C and other serious diseases. Immtech holds the exclusive worldwide licenses to certain patents, patent applications and technology for products derived from a proprietary pharmaceutical platform. For additional information, please go to http://www.immtechpharma.com

"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business, including the future prospects for PCP, which are not historical facts are "forward- looking statements" that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in Immtech's annual report on Form 10-K for the year ended March 31, 2007 and in its other SEC filings and include: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidate, including PCP; (vii) the success of Immtech's clinical trials; (viii) dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to have a third party manufacture its drug candidate at a reasonable cost; (x) Immtech's ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and (xiii) potential exposure to significant product liability.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
2. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
3. Chinese SFDA Grants Immtech Fast Track Status
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016 F ast ... answers at the point ... of scientific, technical and medical information products and services, has launched a ... reviewed clinical information via a mobile device. Elsevier designed the mobile app ... The new app is available in Android and iOS ...
(Date:2/11/2016)... investment" by Bruce Montgomery , one of this area,s most prominent biotech executives, and his ... , PhD. Photo - http://photos.prnewswire.com/prnh/20160211/332242 ... ... ... Kawas said the round was intended to be an $8 million raise but ...
(Date:2/11/2016)...  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) today ... the 38th annual John A. Boswick , ... being held February 14-18, 2016 in Hawaii ... in wound healing, burn care, and infection control, and ... Burns Association, Academy of Physicians in Wound Care and ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... , ... Florida Hospital presents Heart Health Awareness night on Sunday February 14th, ... Amalie Arena. The puck drops at 6:00pm, but fans will have the opportunity to ... the game. The MEGA Heart will be located on Ford Thunder Alley and provide ...
(Date:2/11/2016)... IL (PRWEB) , ... February 11, 2016 , ... ... to the healthcare industry, ranked among the top five firms in the “2015/2016 ... and HIT Implementation Support and Staffing. KLAS is a research and insights firm ...
(Date:2/11/2016)... ... ... In a new paper published in the latest issue ... Rohrich, and colleagues, examine and underscore the importance of upper lateral cartilage in ... this vital area. , The upper lateral cartilage in rhinoplasty, refers to a ...
(Date:2/11/2016)... ... February 11, 2016 , ... "What ... and author Ray Clarke poses a question as a challenge for his readers ... book, "Being in the Being" (published by Partridge Singapore), Clarke explores the subject ...
(Date:2/11/2016)... ... February 11, 2016 , ... Colorado spine surgeon, Donald Corenman, MD, ... spine surgeons to know in 2016 . The list consists of spine surgeons across ... , Dr. Corenman understands the importance of clinical excellence; he has been awarded ...
Breaking Medicine News(10 mins):